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Introduction:
Implantable cardioverter-defibrillator (ICD) is associated 
with reduction in arrhythmic death when implanted for either 
primary or secondary prevention of sudden cardiac death. [1], [2], 
[3], [4], [5]. More than 100,000 ICDs are implanted in the United 
States (US) annually, [6] with the majority of these (about 75%) 
implanted for primary prevention. [6] The mean age of patients 
receiving newimplants is 66 + 13 years and 43% of the new 
implants occur in patients > 70 years of age; [6] however, patients >70 
years of age are underrepresented in the large clinical trials that have 
shown ICD benefit as a whole. A subgroup analysis of MADIT-
II trial showed mortality benefit of ICD in patients > 70 years of 
age in multivariate analysis (HR 1.57, 1.02–2.41, p= 0.042). [7] 
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Abstract
 The median age of patients in major Implantable Cardioverter-defibrillator (ICD)trials (MUSTT, MADIT-I, MADIT-II, and SCD-HeFT) was 63-
67 years; with only 11% ≥70 years. There is little follow-up data on patients over 70 years of age who received an ICD for primary/secondary 
prevention of sudden cardiac death, particularly for veterans.  The aim of this study was to study the natural history of ICD implantation for 
veterans over 70 years of age.  We retrospectively reviewed single center ICD data in 216 patients with a mean age at implantation 76 ± 4 
years. The ICD indication was primary prevention in 161 patients and secondary prevention in 55 patients. The ICD indication was unavailable 
in 4 patients. Mean duration of follow up was 1686 ± 1244 days during which 114 (52%) patients died. Of these, 31% died without receiving 
any appropriate ICD therapy. Overall, 60/216 (28%) received appropriate therapy and 28/216 (13%) received inappropriate therapy. Patients 
who had ICD implantation for secondary prophylaxis had statistically more (p= 0.02) appropriate therapies compared to patients who had 
ICD implantation for primary prevention. Indication for implantation and hypertension predicted appropriate therapy, while age at the time 
of implantation and presence of atrial fibrillation predicted inappropriate therapies. Overall, 7.7% had device related complications. Although 
28% septuagenarians in this study received appropriate ICD therapy, they had high rates of mortality, inappropriate therapy, and device 
complications. ICD implantation in the elderly merits individualized consideration, with higher benefit for secondary prevention.
However, other studies have not shown consistent mortality benefit 
in this population . [8], [9], [10] This is also true in patients receiving an ICD 
for secondary prevention. [11] With advancing age and comorbidity 
burden, the relative contribution of noncardiac or non-arrhythmic 
causes of death [12], [9] may increase compared to younger patients, 
potentially attenuating the benefits of ICD therapy in older patients. 
This might be true even for those who have ICD implanted for 
secondary prevention. The ratio of sudden death to all cause death has 
been shown to fall steadily from 0.51 before age 50, to 0.26 after age 
80, [9] especially in patients with heart failure orfollowing myocardial 
infarction. Thus, one would expect that elderly survivors of cardiac arrest 
may benefit less from the ICD than younger patients. This might be 
especially true in the veteran patient population, which has increased 
cardiovascular risk factors when compared to the general population. 
  Procedural outcomes reported in the ≥70 yr age group have also 
varied considerably with some studies showing increased risk of 
complications in the elderly [13] while others have contradictory 
findings. [14]Current guidelines do not address the criteria or 
prognosis of ICD implantation with advancing age. [8], [9], [10]  Given 
the considerable variation in the reported data, and lack of specific 
guidelines for ICD implantation at an advanced age, we sought 
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to look into the long-term survival and procedural outcomes after 
ICD implantation in the elderly (age > 70 years) veteran population. 
Methods
Study Population
  We retrospectively studied 4800 patients who were enrolled 
in the device clinic at the Richard L Roudebush, Veterans 
Affairs (VA) Medical Center, in Indianapolis, IN. Patients with 
pacemakers were excluded from the study, leaving 1660 patients 
who had an ICD, of which 268 had ICD implanted at or after 
the age of 70 years. Data was incomplete in 48 patients who 
were excluded from further analysis. Thus, a total of 220 patients 
were included in the study for analysis. Patients underwent ICD 
implantation between 1995 and 2014. During the analysis of 
primary versus secondary indication, four patients were further 
excluded because data for indication for implantation was missing. 
The computerized patient record system (CPRS) database was 
reviewed for comorbidities at the time of implantation. This also 
included reading through the scanned data in CPRS for outside 
medical records. Device recordings of patients who had ICD therapies 
were reviewed by an electrophysiologist at the time of clinic visit and 
then adjudicated by a second electrophysiologist (RJ) during the review 
of records for this study. To clarify disagreement in categorization 
of stored events those recordings were presented in the morning 
conference and the consensus agreements were used for analysis. 
Data Collection 
Cormorbidities
 Comorbidities from the CPRS database were recorded 
at the time of initial implantation (or within 6 months 
thereafter). Ejection fraction data was collected through 
echocardiographic, nuclear medicine, or cardiac catheterization 
reports within 6 months prior to the date of ICD implantation. 
Outcomes
     The primary outcomes were all-cause mortality and appropriate 
ICD therapy (anti-tachycardia pacing {ATP} orshock). Secondary 
outcomes include inappropriate therapy (ATP or shock), and 
device-related complications at ≤ 30 days and > 30 days post-
implant. Mortality data was collected through CPRS. The European 
community and the International standards organization have 
provided standard criteria for adverse events observed during 
trials with implantable medical devices, defining an adverse event 
as any undesirable clinical occurrence and taking into account the 
severity and relationship to the implanted device. [15] In our study, 
we excluded inappropriate therapies as device related complication 
(analyzed separately). Adverse events post device implantation 
included lead or device revisions, infections, hematoma, lead fracture, 
and device recalls. This was further subdivided into procedure 
related complications where device recalls were not included.
Statistical Analysis
    Continuous variables were summarized by mean (standard deviation) 
or median (interquartile range) and compared using two-sample T 
test (if the normality assumption holds) or Wilcoxon rank-sum test 
(if the normality assumption did not hold). Normality of distribution 
was determined using the Kolmogorov-Smirnov goodness-of-fit test. 
Categorical data was summarized by frequency and percentage and 
analyzed using Fishers exact test. Distributions of time to death were 
estimated by Kaplan-Meier method and compared using log-rank 
test. Distributions of time to appropriate and inappropriate therapies 
are estimated and compared using the method of sub-distribution 
hazard [16] . Cox proportional hazard models (for mortality) and 
proportional sub-distribution hazard models [17] were used to account 
for baseline covariates. A risk score for total mortality was created 
using risk factors in the multivariate Cox model, where the score is the 
linear sum of the products of the risk factor values and corresponding 
regression coefficients. The score was then rescaled to have a range 
of 0-100, where a higher score indicates a higher risk of death.
Calculation of risk score
 x is the covariate of patient and includes six variables (Age at 
implant, DM, Hyperlipidemia, Atrial Fibrillation, CAD, COPD). 
β is the coefficient vector of the cox model for mortality.
The linear predictor for each patients is defined as lp= xβ
The constant c is defined as C=Maxlp–Minlp/100 
  Maxlp is the maximum value of linear predictor for all patients in the 
sample set, the Minlp is the minimum value of linear predictor for all 
patients in the sample set. 
  The risk score is defined as Score= xβ – Minlp/C. Then we can get the 
increment of the risk score when 1 unit increasing on the respective 
risk factors. 
  All analyses were performed using R 3.0. A two-sided p-value less 
than 0.05 is considered statistically significant.
Results
   A total of 220 patients were included in the study. Baseline 
characteristics of the study population are shown in Table 1. The 
mean age of the study population was 76 ± 4 years. Except for one 
patient all were males. 161 (75%) patients had ICD implanted for 
primary prevention and 55 (25%) patients for secondary prevention. 
Overall, 119 (55%) patients had diabetes, 209 (96%) patients had 
hypertension, 186 (86%) patients had coronary artery disease (CAD), 
76 (35%) patients had atrial fibrillation. Mean left ventricular ejection 
fraction (LVEF) at the time of implantation was 28 + 12%. There 
were 59 (27.3%) patients who had NYHA Class II heart failure 
Table 1: Baseline Characteristics of the Study Population
Parameters Baseline Values (N= 216)
Age (years) 76 ± 4
Male 99%
Primary Prophylaxis Indication 75%
Secondary Prophylaxis Indication 25%
Diabetes 55%
Hypertension 96%
Coronary Artery Disease 86%
Atrial fibrillation 35%
Left ventricular Ejection Fraction at time of 
Implantation
28 ± 12 %
NYHA Class II 27.3%
NYHA Class III 39.3%
GFR at the time of implantation 59 ± 24 ml/min
Beta Blockers 78.2%
ACE-inhibitors/ARB 79.2%
Spironolactone 9.7%
Diuretics 61.5%
Aspirin 79.2%
Dual Antiplatelet Therapy 20%
Anticoagulation 29.1%
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Mortality in Primary Versus Secondary Prevention Group
  There were a total of 114 (52%) deaths. Out of these, 78 (48%) had 
received ICD implantation for a secondary prevention indication, while 
36 (66%) were primary prevention implants. In patients who had the 
ICD implanted for primary prevention of SCD, the 1 year mortality 
was 9% and 5 year mortality was 39%, not significantly different 
as compared to 9% and 40% in the secondary prevention group. 
Appropriate ICD Therapy in Primary Versus Secondary 
Prevention Group
 Of the 60 (27.8%) patients who received appropriate shocks, 33 (20.5%) 
were in patients who had secondary prophylaxis as the indication for 
implantation. In patients who had the ICD implanted for secondary 
prophylaxis, 17% received appropriate shocks in 1 year and 37% within 
5 years compared to 7% and 22% respectively for patients who received 
the ICD for primary prophylaxis. In 55 patients who received ICD 
for secondary prophylaxis, 36 (65.5%) received an appropriate shock. 
(HF) and 85 (39.3%) patients had NYHA Class III HF. Mean 
GFR was 59 ± 24 ml/min. There were 169 (78.2%) patients taking 
beta-blockers, 79.2% (n= 171) on ACE-inhibitors or angiotensin 
receptor blockers (ARBs), 9.7% (n= 22) spironolactone, 61.5% (n= 
133) diuretics, 79.2% (n= 171) aspirin, 20% (n=44) dual antiplatelet 
therapy and 29.1% (n=63) on anticoagulants (primarily warfarin 
26.8% {n=63}). Mean follow up was 1686 ± 1244 days. 116 (53%) 
patients died during this period. At baseline, only atrialfibrillation 
was significantly different (higher in primary prevention 
group, 40.4% versus 20%) between the two groups. (Table 2) 
Overall Data Analysis for Mortality
  Out of 216 patients in the study, 114 (52%) patients died during 
the follow up duration. Out of 114, 35 (31%) received appropriate 
ICD therapy and 16 (14%) had inappropriate therapy. On 
univariate analysis, higher age at the time of implant (HR: 1.07, 
[CI: 1.03, 1.12], p = 0.002) , DM (HR: 1.66, [CI: 1.14, 2.4], p = 
0.008), hyperlipidemia (HR: 1.69, [CI: 1.07, 2.67], p = 0.02), atrial 
fibrillation (HR: 1.54, [CI: 1.05, 2.27], p = 0.03), CAD (HR : 2.39, 
[CI: 1.33, 4.28], p = 0.003) and COPD (HR: 1.94, [CI: 1.31, 2.87], 
p = 0.001) were significantly associated with overall mortality. Age 
at the time of implant (HR: 1.10, [CI: 1.05, 1.15], p = < 0.00010), 
DM (HR: 1.62, [CI: 1.10, 2.40], p = 0.02), CAD (HR: 2.27, [CI: 
1.24, 4.17], p = 0.008) and COPD (HR: 2.40, [CI: 1.60, 3.61], p 
= <0.0001) were significantly associated with mortality when 
applied to a model to develop predictors of mortality in our data.
Overall Data Analysis for Appropriate Therapy
  Out of 216 patients, 60 (28%) received appropriate ICD therapies. 
On univariate analysis, indication for implantation (primary versus 
secondary) {HR: 0.41, (CI: 0.25, 0.68), p = 0.0005}, and hypertension 
{HR: 0.37, (CI: 0.16, 0.83), p = 0.016} were significantly associated 
with appropriate therapy. In a predictive model for appropriate 
Figure 1:
Kaplan Meier Curves comparing incidence of overall mortality, 
appropriate therapies and inappropriate therapies in primary 
versus secondary indication for implantation.
Figure 2:
Kaplan Meier Curves comparing incidence of overall mortality, 
appropriate therapies and inappropriate therapies in patients 
with ischemic versus non ischemic cardiomyopathy.
ICD therapy, secondary prevention indication for implantation 
{HR: 0.43, (CI: 0.26, 0.70), p = 0.0009} and hypertension {HR: 
0.37, (CI: 0.15, 0.95), p = 0.039} were the only two variables 
that predicted appropriate therapy. Patients with a secondary 
prophylaxis indication had 67 times higher risk chance of receiving
appropriate therapy as compared to a primary prevention implant. 
Overall Data Analysis for Inappropriate Therapy
  Of the patients 216 patients, 28 (13%) received inappropriate 
therapies. On univariate analysis, age at the time of implantation 
{HR: 0.87, (CI: 0.80, 0.95), p = 0.003} and presence of atrial fibrillation 
{HR: 2.19, (CI: 1.05, 4.6), p = 0.04} were significantly associated 
with inappropriate therapies. In a predictive model for inappropriate 
therapy, age at time of implantation {HR: 0.87, (CI: 0.79, 0.95), 
p = 0.002} and atrial fibrillation {HR: 2.33, (CI: 1.11, 4.89), p = 
0.025} remained significant predictors of inappropriate therapies. 
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Table 2: Baseline Characteristics
                                         No. of Participants (%)
Characteristics Total (n = 216) Primary (n =161) Secondary (n=55) P Value
Age, mean (SD), y Ischemic 76.38 (4.27) 76.40 (4.23) 76.45 (4.50) 0.94
Yes
No
191 (88.0)
26 (12.0)
139 (86.3)
22 (13.7)
51 (92.7)
4 (7.3)
0.21
DM
Yes
No
119 (54.3)
100 (45.7)
91 (56.9)
69 (43.1)
28 (50.9)
27 (40.1)
0.44
Hypertension
Yes
No
209 (95.0)
11 (5.0)
156 (96.9)
5 (3.1)
51 (92.7)
4 (7.3)
0.18
Smoking status
Current smoker
Former smoker
No smoking
48 (21.9)
70 (32.0)
101 (46.1)
36 (22.5)
52 (32.5)
72 (45.0)
10 (18.2)
18 (32.7)
27 (49.1)
0.78
History of Hyperlipidemia
Yes
No
169 (77.2)
50 (22.8)
126 (78.7)
34 (21.3)
42 (76.4)
13 (23.6)
0.71
GFR time, mean (SD), ml/min 
Chronic Kidney Disease
59.8 (21.3) 59.7 (21.6) 60.3 (20.4) 0.88
Yes
No
91 (41.5)
128 (58.5)
67 (41.9)
93 (58.1)
24 (43.6)
31 (56.4)
0.8
Atrial Fibrillation
Yes
No
76 (34.5)
144 (65.5)
65 (40.4)
96 (59.6)
11 (20.0)
44 (80.0)
0.0063
Coronary artery disease
Yes
No
186 (84.5)
34 (15.5)
138 (85.7)
23 (14.3)
47 (85.5)
8 (14.5)
0.96
Chronic obstructive pulmonary 
disease
Yes
No
62 (28.3)
157 (71.7)
43 (26.9)
117 (73.1)
18 (32.7)
37 (67.3)
0.41
Transient ischemic attack/stroke
Yes
No
18(8.2)
201 (91.8)
15 (9.4)
145(90.6)
3 (5.5)
52 (94.5)
0.37
Inappropriate ICD Therapy in Primary Versus Secondary 
Prevention Group
  Of the 28 patients who received inappropriate shocks, 20 
(12.4%) were in patients who had primary prophylaxis as the 
indication for implantation and the remaining 8 (14.5%) in 
secondary prophylaxis patients. In patients who had the ICD 
implanted for secondary prophylaxis, 6% received inappropriate 
shocks in 1 year and 10% within 5 years compared to 7% and 15% 
respectively for patients who received ICD for primary prophylaxis. 
Adverse events post device implantation
  Twenty-three (10.4%) patients had device related complications. 
Out of these 23 patients, 13 died, 4 received appropriate therapy and 
3 had inappropriate therapy. Two patients had both appropriate and 
inappropriate therapies. Six patients (23%) had complications on the 
day of implant, 23% had within 30 days (excluding those who had on 
the day of implant) and 48% had complications after 30 days of implant.
  Excluding device or lead recalls, 17 had complications (7.7%). The 
complications included infection, hematoma, lead fracture, coronary 
sinus dissection, right ventricular perforation and lead revision.
 
New Risk Score for Overall Mortality
  Based on the available data we looked at possible predictors of overall 
mortality in septuagenarians referred for ICD implantation. A risk 
score was developed based on the variables that were significant for 
mortality in multivariable analysis for mortality. The overall mortality 
based on the risk score is shown in figure 3.  To better understand 
this we can use the following examples: 
1. A 75 year old patient without any risk variables has a score of 6.2.
2. A patient who is 78 years old with diabetes mellitus, no 
hyperlipidemia, no atrial fibrillation, no CAD and no COPD has a 
score of 26.
3. A patient who is 79 years old with diabetes mellitus, hyperlipidemia, 
atrial fibrillation, CAD and COPD has a score of 89.
The survival curves in figure 3 can then be used to predict 1 year and 
5 year mortality in the above patients.
Discussions
  Life expectancy in general population at the age of 70 years is 
14.2 years in males and 16.4 years in females [18]. 53% of our study 
population died during the follow up period of 4.6 years with 1-year 
and 5-year mortality being 19% and 71% respectively. This is consistent 
with other studies with 1-year and 5-year mortality rates of around 
20-40 % and 75-80% respectively in patients with heart failure and 
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of comorbidities. Buxton et [24] also reported a risk stratification 
and found that NYHA class, conduction disturbance, history of 
heart failure, LVEF, atrial fibrillation, and age were predictors 
of mortality. We did not find a difference in mortality in primary 
versus secondary as indication for implantation. However, the above 
mentioned comorbidities were associated significantly with mortality. 
In our study, 16.6 % and 22% of patients who had ICD implanted for 
secondary prophylaxis received appropriate therapy by 1 and 2 years 
respectively. This is much lower than what has been previously reported 
in the Antiarrhythmics Versus Implantable Defibrillator (AVID) trial. 
In that trial, at least one episode of therapy, either ATP or shock, was 
delivered in 51% of patients at 1 year, censoring patients who had died. [3]
In our study 28% received appropriate therapy and 37% died 
without receiving any appropriate therapy. Patients who had ICD 
implanted for secondary prophylaxis were 57 times more likely to 
receive appropriate therapy compared to when primary prophylaxis 
was the indication for implantation. For reasons difficult to explain, 
Table 3a: Survival Analysis for all cause mortality
Parameters Hazard ratio 95% CI p value
Primary or secondary 1.22 ( 0.81 , 1.84 ) 0.334
Age at implant 1.07 ( 1.03 , 1.12 ) 0.00234
Ischemic 1.13 ( 0.62 , 2.08 ) 0.675
DM 1.66 ( 1.14 , 2.42 ) 0.00818
Hypertension 2.60 ( 0.95 , 7.15 ) 0.063
Smoking Status
1.37 ( 0.88 , 2.14 ) 0.159
1.25 ( 0.79 , 1.97 ) 0.343
Hyperlipidemia 1.69 ( 1.07 , 2.67 ) 0.0243
GFR time 0.99 ( 0.98 , 1.00 ) 0.203
Chronic Kidney Disease 1.43 ( 0.99 , 2.08 ) 0.057
Atrial 
Fibrillation
1.54 ( 1.05 , 2.27 ) 0.027
CAD 2.39 ( 1.33 , 4.28 ) 0.00339
COPD 1.94 ( 1.31 , 2.87 ) 0.000922
TIA 0.94 ( 0.48 , 1.87 ) 0.87
LVEF 1.00 ( 0.99 , 1.02 ) 0.591
Table 3b: Multivariate Analysis for All cause mortality
Hazard ratio 95% CI p value
Age at implant 1.10 ( 1.05 , 1.15 ) 0.0000682
DM 1.62 ( 1.10 , 2.40 ) 0.01438
Hyperlipidemia 1.29 ( 0.80 , 2.08 ) 0.29114
Atrial 
Fibrillation
1.47 ( 0.99 , 2.17 ) 0.05559
CAD 2.26 ( 1.23 , 4.15 ) 0.00857
COPD 2.41 ( 1.60 , 3.61 ) 0.0000248
mean age of >70 years [19], [20]. However, it is significantly different 
from the 1-year and 5-year mortality in MADIT- 2 trial comparing 
patients with ICD and no-ICD (8% vs. 10% and 33% vs. 43%) with 
mean age of 64 years [21] and 5-year mortality in the Sudden Cardiac 
Death in Heart Failure Trial SCD-HeFT trial comparing patients 
with ICD and placebo (29% vs 36%) with mean age of 60 years [22].
   Further, in a subgroup analysis of MADIT-2 trial evaluating 204 
elderly patients (aged >75 years) with ischemic cardiomyopathy, there 
was a non-significant trend towards benefit with ICD therapy (HR: 
0.56; 95% CI: 0.29-1.08; P= 0.08). Similarly, subgroup analysis in 
SCD-HeFT [22] and Comparison of Medical Therapy, pacing and 
Defibrillation in Heart Failure (COMPANION) studies [23] also 
showed little mortality benefit. This could be secondary to an increase 
in non-arrhythmic causes of death with increasing age, which is not 
prevented by an ICD. [12] , [9] 
  In our study, age at the time of implant, DM, CAD, COPD 
and atrial fibrillation was predictors of all-cause mortality. 
This is similar to the report of Lee et al. [12] that showed age and 
noncardiac comorbidities influence survival in the care of ICD 
recipients. They used administrative data to show that survival after 
ICD implantation was inversely related to an increasing number 
hypertension was one of the predictors for appropriate therapies. 
The appropriate therapy rate of 6.5% for primary prophylaxis 
is similar to the rate reported in the literature [3], [2]. 
In our study, 7.62 % of patients received inappropriate therapy 
at 2 years, 11% at 45.5 months and 12.9% at 5 years of follow 
up respectively.  This is less than what has been reported in 
MADIT-II [25] and SCD-HeFT trials [22]. In SCD-HeFT, 
[22] 17% of patients received inappropriate shocks over a median 
of 45.5 months of follow-up. Similarly in MADIT-II, 13% of 
IDM: Diabetes Mellitus, GFR: Glomerular filtration rate, CAD: Coronary artery disease, COPD: 
Chronic obstructive pulmonary disease, TIA: Transient ischemic attack, LVEF: Left ventricular 
ejection fraction.
Table 4a: Univariate anlaysis for Appropriate therapy
Parameters Hazard ratio 95% CI p value
Primary or secondary 0.41 ( 0.25 , 0.68 ) 0.00045
Age at implant 0.97 ( 0.91 , 1.04 ) 0.43
Ischemic 0.99 ( 0.46 , 2.16 ) 0.98
DM 1.03 ( 0.62 , 1.70 ) 0.91
Hypertension 0.37 ( 0.16 , 0.83 ) 0.016
Smoking Status
1.10 ( 0.61 , 1.97 ) 0.75
1.18 ( 0.63 , 2.20 ) 0.6
Hyperlipidemia 1.06 ( 0.59 , 1.93 ) 0.84
GFR time 1.00 ( 0.98 , 1.01 ) 0.54
Chronic Kidney 
Disease
1.44 ( 0.87 , 2.37 ) 0.15
Atrial 
Fibrillation
0.80 ( 0.46 , 1.41 ) 0.45
CAD 1.74 ( 0.82 , 3.71 ) 0.15
COPD 1.48 ( 0.88 , 2.50 ) 0.14
TIA 0.96 ( 0.38 , 2.41 ) 0.93
LVEF 1.00 ( 0.98 , 1.02 ) 0.85
DM: Diabetes Mellitus, GFR: Glomerular filtration rate, CAD: Coronary artery disease, COPD: 
Chronic obstructive pulmonary disease, TIA: Transient ischemic attack, LVEF: Left ventricular 
ejection fraction.
Table 4b: Multivariate Analysis for Appropriate Therapy
Hazard ratio 95% CI p value
Primary or secondary 0.43 ( 0.26 , 0.70 ) 0.00081
Hypertension 0.37 ( 0.15 , 0.95 ) 0.039
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reason for inappropriate therapy, combined with the increased 
prevalence of atrial fibrillation with age, likely explains why we found 
associations of age and atrial fibrillation with inappropriate therapy
   Overall device related adverse events in our study population 
was 10.5% which is higher compared to NCDR registry data 
patients had inappropriate shocks during 2 years of follow-up [25]. 
   In these studies, the most common cause of inappropriate 
shocks in decreasing order of frequency were atrial fibrillation; 
supraventricular tachycardia; and oversensing caused by lead 
fracture, T wave oversensing, and electromagnetic interference. 
In our study, age at the time of implant and presence of atrial 
fibrillation (AF) were predictors for inappropriate therapies. This is 
easily understandable. The prevalence of atrial fibrillation increases 
with age [26] with 2.3% at age 40 years and 5.9% at age 65 years. 
Approximately 70% of individuals with AF are between 65 and 85 
years of age [27]. The finding that atrial fibrillation was a primary 
Figure 3a: Overall mortality for subjects with different risk scores
Table 3a.1: Multivariate Analysis for All cause mortality
        1 year Mortality rate and 95 % CI       5 year Mortality rate and 95 % CI
Score=80 0.2122 ( 0.1026 , 0.3217 ) 0.7207 ( 0.5672 , 0.8742 )
Score=60 0.1067 ( 0.0502 , 0.1631 ) 0.4530 ( 0.3230 , 0.5830 )
Score=40 0.0505 ( 0.0210 , 0.0799 ) 0.2419 ( 0.1480 , 0.3357 )
Score=20 0.0243 ( 0.0062 , 0.0424 ) 0.1234 ( 0.0501 , 0.1967 )
Figure 3b: Incremental risk score with different variables.
Variables Incremental Risk Score
Age at implant 2.4 per one year increase
DM 12.6
Hyperlipidemia 6.7
Atrial Fibrillation 10.0
Coronary artery disease 21.2
COPD 22.8
Table 5a: Univariate anlaysis for Inappropriate therapy
Parameters Hazard ratio 95% CI p value
Primary or secondary 0.97 ( 0.44 , 2.15 ) 0.95
Age at implant 0.87 ( 0.80 , 0.95 ) 0.0029
Ischemic
Cardiomyopathy
0.76 ( 0.26 , 2.26 ) 0.62
DM 1.63 ( 0.76 , 3.51 ) 0.21
Hypertension 2.60 ( 0.95 , 7.15 ) 0.063
Smoking Status
0.62 ( 0.24 , 1.58 ) 0.31
1.00 ( 0.41 , 2.43 ) 1
H/o Hyperlipidemia 0.62 ( 0.28 , 1.37 ) 0.23
GFR 1.01 ( 0.99 , 1.03 ) 0.26
Chronic Kidney Disease 0.67 ( 0.30 , 1.47 ) 0.32
Atrial Fibrillation 2.19 ( 1.05 , 4.56 ) 0.037
CAD 1.63 ( 0.48 , 5.55 ) 0.44
COPD 1.26 ( 0.56 , 2.78 ) 0.57
TIA 1.23 ( 0.39 , 3.86 ) 0.72
LVEF 1.01 ( 0.97 , 1.01 ) 0.42
DM: Diabetes Mellitus, GFR: Glomerular filtration rate, CAD: Coronary artery disease, COPD: 
Chronic obstructive pulmonary disease, TIA: Transient ischemic attack, LVEF: Left ventricular 
ejection fraction.
Table 5b: Multivariate Analysis for Inappropriate Therapy
Parameters 95% CI p value
Age at implant ( 0.79 , 0.95 ) 0.0019
Atrial Fibrillation ( 1.11 , 4.89 ) 0.025
with complication rate of 5.8% in 2006 to 4.8% in 2010 in 
patients >65 years of age [28]. However, NDCR doesn’t include 
device recalls as complications. If device/lead recalls are excluded 
from adverse events in our study, the complication rate drops to 
7.7%, which is still higher than 4.8% mentioned above. Possible 
reasons for this higher incidence of complications include:
1. Infection and hematoma could be secondary to a higher 
incidence of advanced comorbidities in this age group.
2. Immunosenescence has been used to describe loss of immune 
functions in elderly individuals (> 65 years old). Although 
the mechanisms leading to immunosenescence are not clear, 
it has been associated with increased susceptibility to disease, 
infections, and poor response to treatments and vaccination [29].
Limitations
  There are several limitations of this study. First, it is a retrospective 
study with a relatively small sample size. A detailed review of the 
records was done which included review of outside records, which 
were scanned in the CPRS. However, there could have been some 
arrhythmia episodes (therapy), which might have been missed 
and not recorded in the system. The veteran population is special 
with a different set of comorbidities from the general population 
and therefore the results of this study might not be generalized 
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2. Connolly, S.J., et al., Canadian implantable defibrillator study (CIDS) : a 
randomized trial of the implantable cardioverter defibrillator against amiodarone. 
Circulation, 2000. 101(11): p. 1297-302.
3. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in 
patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics 
versus Implantable Defibrillators (AVID) Investigators. N Engl J Med, 1997. 
337(22): p. 1576-83.
4. Kuck, K.H., et al., Randomized comparison of antiarrhythmic drug therapy with 
implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac 
Arrest Study Hamburg (CASH). Circulation, 2000. 102(7): p. 748-54.
5. Connolly, S.J., et al., Meta-analysis of the implantable cardioverter defibrillator 
secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics 
vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian 
Implantable Defibrillator Study. Eur Heart J, 2000. 21(24): p. 2071-8.
6. Kremers, M.S., et al., The National ICD Registry Report: version 2.1 including 
leads and pediatrics for years 2010 and 2011. Heart Rhythm, 2013. 10(4): p. e59-
65.
7. Goldenberg, I., et al., Risk stratification for primary implantation of a cardioverter-
defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll 
Cardiol, 2008. 51(3): p. 288-96.
8. Panotopoulos, P.T., et al., Efficacy of the implantable cardioverter-defibrillator in 
the elderly. J Am Coll Cardiol, 1997. 29(3): p. 556-60.
9. Krahn, A.D., et al., Diminishing proportional risk of sudden death with advancing 
age: implications for prevention of sudden death. Am Heart J, 2004. 147(5): p. 
to the overall population. We propose a newer scoring system to 
estimate overall mortality when the patient is first seen in the 
clinic for an ICD. This needs validation in prospective study.
 However, this is an important step for futureprospective 
studies, which might lead to a new section in 
ICD guidelines, addressing this specific age group
Conclusion
  To our knowledge, our study represents the first attempt to look 
into the natural history of ICDs when implanted at ≥70 years of 
age in veterans. This is a very special population with multiple 
different comorbidities. The findings from this study suggest that 
ICD implantation in the elderly should be given individualized 
consideration. We believe that current criteria for ICD implantation 
cannot be fully applied to this age group and prospective studies are 
needed for better define this age group. 
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